SCHEMBL4892745

SCHEMBL4892745

CC(C)(C)OC(=O)NC1CCN(c2nccs2)CC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.58
CKS1B P61024 1/20 0.51
SKP1 P63208 1/20 0.51
SKP2 Q13309 1/20 0.51
HPGDS O60760 1/20 0.50
HTT P42858 1/20 0.48
HSD17B10 Q99714 1/20 0.48
HRH3 Q9Y5N1 1/20 0.47
CTSK P43235 2/20 0.44
ALDH1A1 P00352 1/20 0.44
PDE10A Q9Y233 1/20 0.43
NAMPT P43490 1/20 0.42
KDM1A O60341 1/20 0.42
MAOB P27338 1/20 0.42
KCNA3 P22001 1/20 0.42
PIM1 P11309 1/20 0.42
PIM3 Q86V86 1/20 0.42
PIM2 Q9P1W9 1/20 0.42
PARP1 P09874 1/20 0.42
ADORA2A P29274 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL973857 0.93 HPGD (0.50) HPGDCKS1BSKP1SKP2HPGDS
SCHEMBL972766 0.88 HPGD (0.45) HPGDCKS1BSKP1SKP2HTT
SCHEMBL30807275 0.86 BTK (0.55) HPGDCTSKPDE10A
SCHEMBL30807324 0.86 BTK (0.55) HPGDCTSKPDE10A
SCHEMBL30807327 0.83 HPGD (0.46) HPGDHPGDSHTTHSD17B10HRH3
SCHEMBL25520140 0.81 DPP4 (0.44) HPGDHPGDSHTTHSD17B10HRH3
SCHEMBL1956790 0.80 CYP3A4 (0.49) CKS1BSKP1SKP2CTSKKCNA3
SCHEMBL30807279 0.80 ALDH1A1 (0.60) HPGDHTTHSD17B10HRH3ALDH1A1
SCHEMBL4954279 0.80 GPR119 (0.61) CKS1BSKP1SKP2CTSKPDE10A
SCHEMBL27440742 0.80 CKS1B (0.50) CKS1BSKP1SKP2CTSKKCNA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4577211-A2 PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER Wake Forest University Health Sciences (US) 2025-07-02 EP disclosed
EP-4339193-A1 COMPOUND HAVING ANTI-TUMOR ACTIVITY AND USE THEREOF Innovstone Therapeutics Limited (CN) 2024-03-20 EP disclosed
WO-2024044744-A2 PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) 2024-02-29 WO disclosed
WO-2024044751-A2 PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) 2024-02-29 WO disclosed
WO-2022237858-A1 COMPOUND HAVING ANTI-TUMOR ACTIVITY AND USE THEREOF 上海翊石医药科技有限公司 2022-11-17 WO disclosed
US-8318774-B2 N-(3-((thiazol-2-yl)amino)propyl)-3-phenylpropiolamide, 4-(thiazol-2-yl-amino)-1-(3-phenyl-propiolyl)piperidine, for example; for preventing or treating a disorder or disease that is mediated at least in part by mGluR26 receptors, such as pain, migraines, depression, neurodegenerative diseases GRUENENTHAL GMBH (DE) 2012-11-27 US disclosed
US-20080269295-A1 SUBSTITUTED THIAZOLES AND THEIR USE FOR PRODUCING DRUGS GRUNENTHAL GMBH (DE) 2008-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269295-A1 SUBSTITUTED THIAZOLES AND THEIR USE FOR PRODUCING DRUGS TPMT, ABCB1, FDPS HPGD 804/4885CKS1B 3811/4885SKP1 3475/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.